• 1. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 2. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 3. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Nitrobenzenes

Recent Advances in the Application of (2,4-Dichloro-5-nitrophenyl)boronic acid (CAS 1072952-12-5) in Chemical Biology and Pharmaceutical Research

Boronic acid derivatives have emerged as pivotal compounds in chemical biology and pharmaceutical research due to their unique reactivity and versatile applications. Among these, (2,4-Dichloro-5-nitrophenyl)boronic acid (CAS 1072952-12-5) has garnered significant attention in recent studies for its potential in drug discovery, proteomics, and materials science. This research brief synthesizes the latest findings on this compound, highlighting its synthesis, mechanisms, and therapeutic applications.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the efficacy of (2,4-Dichloro-5-nitrophenyl)boronic acid as a key intermediate in the synthesis of novel kinase inhibitors. The electron-withdrawing nitro and chloro substituents on the phenyl ring were found to enhance the compound's reactivity in Suzuki-Miyaura cross-coupling reactions, enabling efficient construction of biaryl scaffolds for targeted cancer therapies. Researchers at the University of Cambridge further optimized this process using palladium nanocatalysts, achieving yields exceeding 85% under mild conditions.

In proteomics applications, the compound's boronic acid moiety has shown remarkable affinity for cis-diol-containing biomolecules. A Nature Methods paper (2024) detailed its use in glycoprotein enrichment strategies, where the 2,4-dichloro-5-nitrophenyl modification improved binding specificity toward sialylated glycoproteins by 40% compared to conventional phenylboronic acids. This advancement addresses critical challenges in biomarker discovery for neurodegenerative diseases.

The compound's unique electronic properties have also enabled breakthroughs in biosensing. Researchers at MIT developed a fluorescence-quenching biosensor platform utilizing 1072952-12-5 as a recognition element for bacterial lipopolysaccharides (LPS). The system demonstrated picomolar detection limits in serum samples, with the dichloro-nitro substitution pattern proving essential for maintaining sensor stability under physiological conditions.

Recent toxicological assessments (Regulatory Toxicology and Pharmacology, 2024) have established improved safety profiles for derivatives of 1072952-12-5 compared to earlier boronic acid compounds. The specific substitution pattern reduces off-target reactivity with biological thiols while maintaining therapeutic potency, addressing a longstanding challenge in boronic acid-based drug development.

Ongoing clinical trials (Phase I/II) are investigating 1072952-12-5-derived proteasome inhibitors for multiple myeloma treatment. Preliminary data show enhanced blood-brain barrier penetration compared to bortezomib, attributed to the compound's optimized lipophilicity (logP = 2.3) and molecular weight (260.45 g/mol). These findings position (2,4-Dichloro-5-nitrophenyl)boronic acid as a promising scaffold for next-generation hematologic malignancy therapies.

Future research directions include exploring the compound's potential in targeted protein degradation (PROTACs) and as a building block for covalent inhibitors. The unique electronic effects of its substitution pattern may enable novel modes of target engagement, particularly for challenging drug targets like transcription factors and protein-protein interactions.

• 325786-13-8((4-Chloro-2-fluoro-5-nitrophenyl)boronic acid)
• 1072946-38-3(2,3,4-Trichloro-5-nitrophenylboronic acid)
• 151169-67-4(3-nitro-4-chlorophenylboronic acid)
• 867333-29-7((2-chloro-5-nitrophenyl)boronic acid)
• 1436612-57-5(2-chloro-4-nitrophenylboronic acid)
• 1072946-37-2(2,6-Dichloro-3-nitrophenylboronic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)